Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H
暂无分享,去创建一个
W. Tillett | L. Kristensen | A. Bradley | M. Okada | K. de Vlam | C. El Baou | J. Dutz | C. Sapin | G. Mészáros | S. L. Leage